A first-in-human phase I trial of ADXS 11001 in patients with advanced, metastatic cervical cancer who have failed first line therapy.

Trial Profile

A first-in-human phase I trial of ADXS 11001 in patients with advanced, metastatic cervical cancer who have failed first line therapy.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2010

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advaxis
  • Most Recent Events

    • 29 Jul 2010 Ongoing follow-up of surviving patients has shown that the patients who were alive in March are still alive, 3.5 and 3.9 years after initial dosing, according to an Advaxis media release.
    • 23 Mar 2010 Ongoing follow up of surviving patients has shown that two of 15 treated patients are still alive 1,248 and 1,128 days after initial dosing, according to an Advaxis media release.
    • 29 Dec 2009 Updated survival results reported in an Advaxis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top